U.S. development Phase success rates for rare and common disease drugs 2011-2020

Probability of success for new rare disease and high prevalence disease drugs in the U.S. by development phase from 2011 to 2020

Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

February 2021

Region

United States

Survey time period

January 1, 2011, to November 30, 2020

Supplementary notes

Only company-sponsored, FDA registration-enabling development programs were included in this analysis. Investigator-sponsored studies and combinations with other investigational drugs were excluded.
* NDA - New Drug Application / BLA - Biologic License Application.

Citation formats
Statista Accounts: Access All Statistics. Starting from $2,148 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD $179 USD / Month *
in the first 12 months
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Orphan drugs "

Other statistics that may interest you Orphan drugs

Rare diseases

4

Market overview

5

Companies

4

Products

6

Research and development

6

Further related statistics

17
Statista Accounts: Access All Statistics. Starting from $2,148 USD / Year
Learn more about how Statista can support your business.